Table 3 Comparison of CYP2C9*1 and *2 alleles as well as CYP2C19 alleles in various study groups
CYP2C9*1 VERSUS CYP2C9*2 | |||
|---|---|---|---|
Genotypes | Phenytoin-induced dose-related ADRs (n = 66) Number of patients (%age) | No ADR (Group 2) (n = 100) Number of patients (%age) | p value |
CYP2C9*1/*1 | 54 (81.81%) | 87 (87%) | 1*/2* versus 1*/1* p = 0.53 2*/2* versus 1*/1* p = 0.51 |
CYP2C9*1/*2 | 7 (10.60%) | 8 (8%) | |
CYP2C9*2/*2 | 5 (7.57%) | 5 (5%) | |
CYP2C19*1 VERSUS CYP2C19*2 | |||
|---|---|---|---|
Genotypes | Phenytoin-induced dose-related ADRs (n = 66) Number of patients (%age) | No ADR (n = 100) (Group 2) Number of patients (%age) | p |
CYP2C9*1/*1 | 44 (66.66%) | 68 (68%) | 1*2* versus 1*/1* p = 0.84 2*/2* versus 1*/1* p = 1 |
CYP2C9*1/*2 | 16 (24.24%) | 23 (23%) | |
CYP2C9*2/*2 | 6 (9.09%) | 9 (9%) | |
CYP2C19*1 VERSUS CYP2C19*3 | |||
|---|---|---|---|
|  | Phenytoin-induced dose-related ADRs (n = 66) Number of patients (%age) | No ADR (n = 100) (Group 2) Number of patients (%age) | p |
CYP2C19*1/*1 | 66 (100%) | 100 (100%) | 1 |
CYP2C19*1/*3 | 0 (0%) | 0 (0%) | |
CYP2C19*3/*3 | 0 (0%) | 0 (0%) | |